JP2020525425A - 小胞体ストレスの治療管理のためのガルシノール組成物 - Google Patents

小胞体ストレスの治療管理のためのガルシノール組成物 Download PDF

Info

Publication number
JP2020525425A
JP2020525425A JP2019570406A JP2019570406A JP2020525425A JP 2020525425 A JP2020525425 A JP 2020525425A JP 2019570406 A JP2019570406 A JP 2019570406A JP 2019570406 A JP2019570406 A JP 2019570406A JP 2020525425 A JP2020525425 A JP 2020525425A
Authority
JP
Japan
Prior art keywords
garcinol
stress
endoplasmic reticulum
toxicity
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525425A5 (enExample
Inventor
ムハンメド マジード
ムハンメド マジード
カリヤナム ナガブシャナム
カリヤナム ナガブシャナム
ラクシュミ ムンドクル
ラクシュミ ムンドクル
Original Assignee
サミ ラブズ リミテッド
サミ ラブズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミ ラブズ リミテッド, サミ ラブズ リミテッド filed Critical サミ ラブズ リミテッド
Publication of JP2020525425A publication Critical patent/JP2020525425A/ja
Publication of JP2020525425A5 publication Critical patent/JP2020525425A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2019570406A 2017-06-22 2018-06-22 小胞体ストレスの治療管理のためのガルシノール組成物 Pending JP2020525425A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523592P 2017-06-22 2017-06-22
US62/523,592 2017-06-22
PCT/US2018/038950 WO2018237243A1 (en) 2017-06-22 2018-06-22 Garcinol compositions for therapeutic management of endoplasmic reticulum stress

Publications (2)

Publication Number Publication Date
JP2020525425A true JP2020525425A (ja) 2020-08-27
JP2020525425A5 JP2020525425A5 (enExample) 2021-06-10

Family

ID=64691689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570406A Pending JP2020525425A (ja) 2017-06-22 2018-06-22 小胞体ストレスの治療管理のためのガルシノール組成物

Country Status (7)

Country Link
US (1) US20180369166A1 (enExample)
EP (1) EP3614846A4 (enExample)
JP (1) JP2020525425A (enExample)
KR (1) KR20200011492A (enExample)
AU (1) AU2018290320A1 (enExample)
CA (1) CA3065332A1 (enExample)
WO (1) WO2018237243A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317776A (zh) * 2019-07-31 2019-10-11 遵义医学院附属医院 一种内质网应激细胞模型的建立方法
CN111454350B (zh) * 2020-06-01 2020-12-29 广东丸美生物技术股份有限公司 一种重组纤连蛋白突变体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11139965A (ja) * 1997-11-06 1999-05-25 Kikkoman Corp 抗腫瘍薬
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
US20070254961A1 (en) * 2003-11-13 2007-11-01 Jawaharlal Nehru Centre For Advanced Scientific Research Polyisoprenylated Benzophenones and Their Isomers as Inhibitors of Histone Acetyltransferases and Uses thereof
JP2012065644A (ja) * 2010-06-14 2012-04-05 Nissan Chem Ind Ltd 造血幹細胞の製造方法
JP2014502621A (ja) * 2010-12-30 2014-02-03 ムハンメド マジード ガルシノールの肝臓保護活性
JP2014503514A (ja) * 2010-12-09 2014-02-13 インダス・バイオテック・プライベート・リミテッド ガルシノール、シクロデキストリンの複合体およびその方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710976D0 (en) * 2007-06-07 2007-07-18 Bioalvo Am Screening method
WO2010036711A1 (en) * 2008-09-23 2010-04-01 Bach Pharma Inc. Methods of modulating protein homeostasis, metabolic syndrome, heavy metal intoxication and nrf2 transcription factors
US20120207744A1 (en) * 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
EP2461694A4 (en) * 2009-08-06 2013-06-19 Neuraltus Pharmaceuticals Inc TREATMENT OF MACROPHONE-CONDITIONAL DISORDER
US8329743B2 (en) * 2011-01-10 2012-12-11 Sami Labs Limited Compositions and its use in treating obesity or inducing weight loss
WO2015049553A1 (en) * 2013-10-03 2015-04-09 Delhi Institute Of Pharmaceutical Sciences And Research Effect of garcinol in delaying the progression of diabetic nephropathy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11139965A (ja) * 1997-11-06 1999-05-25 Kikkoman Corp 抗腫瘍薬
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
US20070254961A1 (en) * 2003-11-13 2007-11-01 Jawaharlal Nehru Centre For Advanced Scientific Research Polyisoprenylated Benzophenones and Their Isomers as Inhibitors of Histone Acetyltransferases and Uses thereof
JP2012065644A (ja) * 2010-06-14 2012-04-05 Nissan Chem Ind Ltd 造血幹細胞の製造方法
JP2014503514A (ja) * 2010-12-09 2014-02-13 インダス・バイオテック・プライベート・リミテッド ガルシノール、シクロデキストリンの複合体およびその方法
JP2014502621A (ja) * 2010-12-30 2014-02-03 ムハンメド マジード ガルシノールの肝臓保護活性

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEMSHEKHAR, M., ET AL.: "An overview on genus garcinia: phytochemical and therapeutical aspects", PHYTOCHEM REV, vol. 10, JPN6022003021, 2011, pages 325 - 351, XP019933549, ISSN: 0004863786, DOI: 10.1007/s11101-011-9207-3 *

Also Published As

Publication number Publication date
WO2018237243A1 (en) 2018-12-27
US20180369166A1 (en) 2018-12-27
AU2018290320A1 (en) 2020-02-06
CA3065332A1 (en) 2018-12-27
EP3614846A4 (en) 2021-01-13
EP3614846A1 (en) 2020-03-04
KR20200011492A (ko) 2020-02-03

Similar Documents

Publication Publication Date Title
Berghoff et al. Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis
Yousefzadeh et al. Fisetin is a senotherapeutic that extends health and lifespan
Zhang et al. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS‐mediated NLRP 3 inflammasome activation
Hirsova et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes
He et al. Circulating Peroxiredoxin-1 is a novel damage-associated molecular pattern and aggravates acute liver injury via promoting inflammation
Zhao et al. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury
Xu et al. Coenzyme Q10 improves lipid metabolism and ameliorates obesity by regulating CaMKII-mediated PDE4 inhibition
Ni et al. Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity
Solini et al. The purinergic 2X7 receptor participates in renal inflammation and injury induced by high‐fat diet: possible role of NLRP3 inflammasome activation
Gieling et al. Interleukin-1 participates in the progression from liver injury to fibrosis
Zhao et al. Chlorogenic acid alleviates chronic stress-induced duodenal ferroptosis via the inhibition of the IL-6/JAK2/STAT3 signaling pathway in rats
Wei et al. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells
You et al. Macrophages directly mediate diabetic renal injury
Petrasek et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Xing et al. Advanced glycation end products induce atherosclerosis via RAGE/TLR4 signaling mediated‐m1 macrophage polarization‐dependent vascular smooth muscle cell phenotypic conversion
Cao et al. Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway
Wei et al. Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4α miR122 pathway
JP2021119180A (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
Morrison et al. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR−/−. Leiden mice
Fransson et al. b-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome
Liang et al. Advanced oxidation protein products induce endothelial-to-mesenchymal transition in human renal glomerular endothelial cells through induction of endoplasmic reticulum stress
Fang et al. Autophagy inhibition induces podocyte apoptosis by activating the pro-apoptotic pathway of endoplasmic reticulum stress
US20250099553A1 (en) Composition and methods for modulation of elovl2
Ouyang et al. FGF21 attenuates high uric acid‑induced endoplasmic reticulum stress, inflammation and vascular endothelial cell dysfunction by activating Sirt1
Cao et al. Sitagliptin reduces endothelial dysfunction and apoptosis induced by high-fat diet and palmitate in thoracic aortas and endothelial cells via ROS-ER stress-CHOP pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220831